Prävention – Lohnt sich Prävention für die gesetzlichen - Krankenkassen in Deutschland?

Weinhold et al. Economic impact of disease prevention in a morbidity-based financing system: does prevention pay off for a statutory health insurance fund in Germany? Eur J Health Econ 2019; 20 (8): 1181–1193 Das deutsche Gesundheitssystem wird durch vermeidbare chronische Erkrankungen in besonderem Maße belastet. Die Finanzierung geeigneter Präventionsmaßnahmen obliegt den Krankenkassen. Weinhold et al. untersuchten in einer retrospektiven Studie die ökonomischen Auswirkungen von Prävention für die GKV.

Internal Quality Control in Osteopathic Healthcare Delivery

Introduction. The work presents an analysis of certain juridical, theoretical and practical problems of organization of internal quality control of medical aid (hereafter referred to as IQCMA) from the moment of history taking and diagnostics till the end of the treatment (quality of technologies and of the results obtained). A model of IQCMA conditioned by the quality of technologies and the results obtained has been proposed.Objects of research. Laws, departmental regulatory acts of the Ministry of Health of the Russian Federation, of the Federal Statutory Health Insurance Fund, orders about IQCMA approved by the authorized bodies of the subjects of the Russian Federation.Methods. Hypothetico-deductive method, general logical methods and research techniques (analysis, synthesis, abstracting, generalization, induction).

Migraine Prescription Density and Recommendations. Results of the pcaom Study

We estimate the extent to which recommendations on the prevention and treatment of migraine issued by professional medical bodies are implemented in medical practice in Germany. Computerized data (MediPlus, IMS Health) were analyzed in 4,636 male and 16,573 female migraineurs from 383 primary care practices 1994 through 1996 (Primary Care of Migraine, PCAOM study). A total of 90,540 drug prescriptions with a documented diagnosis of migraine were issued in 45,669 person-years (1.492 prescriptions [DM 40.99] per person-year to men, 2.109 prescriptions [DM 62.01] per person-year to women). Approximately three of every four prescriptions were incompatible with the recommendations of the German Migraine and Headache Society (DMKG), amounting to extrapolated costs of DM 49 million per year borne by the German statutory health insurance fund for combination migraine preparations. The density of non-DMKG therapies for diagnosed migraine followed a sigmoid curve with increasing patient age, while DMKG-compliant therapies described a bell-shaped curve. Referrals to neurological care specialists were not associated with subsequent primary care focus on recommended therapies. We conclude that medication prescribed for migraine is largely not according to long-standing recommendations by medical societies in Germany.